Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2025
Business Overview: BMS operates as a single segment focused on the discovery, development, and commercialization of innovative medicines for serious diseases, primarily in oncology, hematology, immunology, cardiovascular, and neuroscience.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $11,201 | $11,865 |
| Net Earnings/(Loss) Attributable to BMS | $2,456 | $(11,911) |
| Diluted EPS (GAAP) | $1.20 | $(5.89) |
| Diluted EPS (Non-GAAP) | $1.80 | $(4.40) |
| Operating Cash Flow | $1,954 | $2,834 |
| Free Cash Flow (Approx.) | $1,694 | $2,550 |
| Total Debt (Short-term + Long-term) | $49,711 | $49,649 |
| Cash and Cash Equivalents | $10,875 | $9,334 |
| Net Debt Position | $(37,584) | $(38,470) |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($260M in Q1 2025, $284M in Q1 2024).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 6% to $11.2 billion. This was driven by a 7% decline in U.S. revenues and a 3% decline in International revenues.
- Legacy Portfolio: Significant declines in Revlimid (-44%), Sprycel (-53%), and Abraxane (-52%) due to generic erosion. Eliquis revenues decreased 4% due to the redesign of the U.S. Medicare Part D program.
- Growth Portfolio: Increased 16% to $5.6 billion, led by strong performance in Opdivo (+9%), Breyanzi (+146%), Camzyos (+89%), and Reblozyl (+35%).
- Profitability Turnaround: The company returned to profitability with $2.46 billion in net earnings, compared to a loss of $11.9 billion in Q1 2024.
- Acquired IPRD: A massive reduction in non-cash charges occurred. Q1 2024 included a $12.1 billion charge for the Karuna acquisition and $800 million for SystImmune. Q1 2025 Acquired IPRD was only $188 million.
- Amortization: Amortization of acquired intangible assets dropped 65% to $830 million, largely because the Revlimid asset was fully amortized in Q4 2024.
- Expense Reduction: Selling, General and Administrative (SG&A) expenses fell 33% and R&D expenses fell 16%, driven by the absence of one-time acquisition-related stock award settlements in 2025 and ongoing productivity initiatives.
Guidance, Outlook, and Risks
- Restructuring: BMS expanded its 2023 Restructuring Plan, now expecting total charges of approximately $2.5 billion through 2027, with $1.2 billion incurred to date. The company targets annual cost savings of $2.0 billion by the end of 2027.
- Regulatory Approvals: Recent approvals include Opdivo + Yervoy for hepatocellular carcinoma (HCC) and colorectal cancer (CRC) in the U.S. and EU, and Camzyos for obstructive HCM in Japan.
- Pipeline Updates:
- Positive: Sotyktu met primary endpoints for psoriatic arthritis; Opdivo showed improved overall survival in neoadjuvant NSCLC.
- Negative: Camzyos failed to meet primary endpoints in the Phase III ODYSSEY-HCM trial for non-obstructive HCM. Cobenfy failed to meet statistical significance as an adjunctive treatment in the Phase III ARISE trial for schizophrenia.
- Risks and Contingencies:
- Government Pricing: The Inflation Reduction Act (IRA) continues to impact pricing, with Eliquis subject to price negotiation starting in 2026 and Pomalyst selected for negotiation starting in 2027.
- Legal Proceedings: Ongoing litigation includes patent challenges for Eliquis in Europe, securities litigation regarding Celgene CVRs, and pricing/promotional practices disputes (e.g., Plavix in Hawaii).
- Acquisitions: BMS entered a definitive agreement to acquire 2seventy bio (Abecma) for ~$286 million, expected to close in Q2 2025.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of Growth Portfolio gains (Opdivo, Breyanzi) against the accelerating erosion of Legacy products (Revlimid, Eliquis) due to generics and Medicare Part D changes.
- One-Time Items: Confirm that the Q1 2024 loss was driven by non-recurring Acquired IPRD charges ($12.9B) to accurately assess the underlying operational improvement in Q1 2025.
- Restructuring Costs: Monitor the remaining $1.3 billion in expected restructuring charges through 2027 and the realization of the targeted $2.0 billion in annual cost savings.
- Legal Exposure: Review the status of the Celgene CVR litigation and the outcome of the Plavix Hawaii appeal, as these could result in significant future liabilities.
- Pipeline Execution: Assess the impact of the failed Camzyos (nHCM) and Cobenfy (schizophrenia adjunct) trials on future revenue projections and R&D efficiency.